NewYork-Presbyterian’s behavioral health experts provide cutting-edge psychiatric care for a range of conditions and are committed to researching breakthrough treatment options that improve patient outcomes for a growing population of people living with mental health disorders. In 2025, clinicians and researchers from Columbia and Weill Cornell Medicine made significant advancements in identifying new therapeutic targets for anxiety, integrating care for ADHD and concurrent alcohol use disorder, developing AI-based tools to predict schizophrenia risk, and more. These developments are paving the way for advanced treatments and therapies that will benefit more patients.
Our distinguished child, adolescent, and adult psychiatric experts from Columbia and Weill Cornell Medicine are dedicated to improving quality of life for individuals living with mental health conditions through pharmacotherapy, psychotherapies, and neurostimulation. Our clinical care is complemented by pioneering research initiatives in novel therapeutics, functional neuroimaging, basic neuroscience, and genetics.
Psychiatry
Stay up to date with the latest in Psychiatry
The NYP Advances newsletter delivers groundbreaking research and advancements straight to your inbox.
Featured Updates
Neurology & NeurosurgeryCerebral Organoids Provide New Strategy to Personalize Glioblastoma Treatment
Cerebral Organoids Provide New Strategy to Personalize Glioblastoma Treatment
On this episode of Advances in Care, Erin Welsh is joined by Dr. Howard Fine, a neuro-oncologist at NewYork-Presbyterian and director of the Brain Tumor Center at Weill Cornell Medicine, to explore his pioneering research on glioblastoma, the most common and aggressive form of brain cancer.
Podcast
Episode 48
Stay up to date with the Advances newsletter
Get the latest groundbreaking research and advancements in medicine delivered to your inbox.
